Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI Oxaliplatin and Fluorouracil in Unresectable Biliary Tract Carcinomas
NCT01572324Phase 2Completed
- Sponsor
- Peking University
- Start
- Mar 2012
- Primary completion
- Oct 2015
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin and fluorouracil in biliary tract cancer (BTC), sponsored by Peking University. Primary endpoint: Response rates at 4 months. Started Mar 2012; status: completed.
02
Drugs
oxaliplatinfluorouracil
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT01572324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01572324.